Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Merims

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
MHC class I-independent recognition of NK-activating receptor KIR2DS4Gil Katz, Roi Gazit, Tal I Arnon, et al.
Cancer Immunology Research|January 7, 2018
Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>Galit Eisenberg, Roni Engelstein, Anat Geiger-Maor, et al.
Immunologic Research|July 22, 2022
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphomaRony Shreberk-Hassidim, Anat Geiger-Maor, Galit Eisenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 27, 2016
Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBLRoni Engelstein, Sharon Merims, Galit Eisenberg, et al.
Clinical Chemistry and Laboratory Medicine|May 17, 2018
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseasesPanagiota S Filippou, Annie H Ren, Dimitrios Korbakis, et al.
JAAD International|November 17, 2025
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemicsDeborah Korn, Sivan Sheffer-Levi, Maayan Eitan-Wexler, et al.
Elife|March 4, 2020
SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpointEmma Hajaj, Galit Eisenberg, Shiri Klein, et al.
Cancer Immunology Research|March 25, 2021
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector FunctionsEmma Hajaj, Elad Zisman, Shay Tzaban, et al.
Journal of Immunology Research|June 14, 2016
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 BlockadeMichal Lotem, Sharon Merims, Stephen Frank, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
MHC class I-independent recognition of NK-activating receptor KIR2DS4Gil Katz, Roi Gazit, Tal I Arnon, et al.
Cancer Immunology Research|January 7, 2018
Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>Galit Eisenberg, Roni Engelstein, Anat Geiger-Maor, et al.
Immunologic Research|July 22, 2022
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphomaRony Shreberk-Hassidim, Anat Geiger-Maor, Galit Eisenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 27, 2016
Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBLRoni Engelstein, Sharon Merims, Galit Eisenberg, et al.
Clinical Chemistry and Laboratory Medicine|May 17, 2018
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseasesPanagiota S Filippou, Annie H Ren, Dimitrios Korbakis, et al.
JAAD International|November 17, 2025
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemicsDeborah Korn, Sivan Sheffer-Levi, Maayan Eitan-Wexler, et al.
Elife|March 4, 2020
SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpointEmma Hajaj, Galit Eisenberg, Shiri Klein, et al.
Cancer Immunology Research|March 25, 2021
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector FunctionsEmma Hajaj, Elad Zisman, Shay Tzaban, et al.
Journal of Immunology Research|June 14, 2016
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 BlockadeMichal Lotem, Sharon Merims, Stephen Frank, et al.
Pageof 3